UCB S A/ADR (OTCMKTS:UCBJY) Stock Passes Above 50 Day Moving Average of $38.56

Share on StockTwits

Shares of UCB S A/ADR (OTCMKTS:UCBJY) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $38.56 and traded as high as $40.00. UCB S A/ADR shares last traded at $40.00, with a volume of 463 shares traded.

Separately, Goldman Sachs Group upgraded shares of UCB S A/ADR from a “neutral” rating to a “buy” rating in a research report on Thursday, May 30th.

COPYRIGHT VIOLATION NOTICE: “UCB S A/ADR (OTCMKTS:UCBJY) Stock Passes Above 50 Day Moving Average of $38.56” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/4379952/ucb-s-a-adr-otcmktsucbjy-stock-passes-above-50-day-moving-average-of-38-56.html.

UCB S A/ADR Company Profile (OTCMKTS:UCBJY)

UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome.

Featured Story: Sell-Side Analysts

Receive News & Ratings for UCB S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report